<div id="readability-page-1"><div>Overview<ul><li>CollPlant Q3 2025 revenue increased significantly due to higher rhCollagen product sales</li><li>Company announces 25% workforce reduction to extend cash runway</li><li>CollPlant expands North American distribution through new U.S. logistics partnership</li></ul>Outlook<ul><li>CollPlant expects North American logistics center to be operational this quarter</li><li>Company plans to prioritize collaboration with AbbVie in 2026</li><li>CollPlant seeks strategic partner for regenerative breast implant development</li></ul>Result Drivers<ul><li>RH COLLAGEN SALES - Increased sales of rhCollagen products contributed to revenue growth</li><li>ABBVIE MILESTONE PAYMENT - $2 mln milestone payment from AbbVie boosted revenue</li></ul>Key Details<div><table><tbody><tr><td>Metric</td><td>Beat/Miss</td><td>Actual</td><td>Consensus Estimate</td></tr><tr><td>9M Revenue</td><td></td><td>$2.30 mln</td><td></td></tr><tr><td>9M Adjusted EPS</td><td></td><td>-$0.58</td><td></td></tr><tr><td>9M EPS</td><td></td><td>-$0.69</td><td></td></tr><tr><td>9M Adjusted Net Income</td><td></td><td>-$7 mln</td><td></td></tr><tr><td>9M Net Income</td><td></td><td>-$8.30 mln</td><td></td></tr><tr><td>9M Operating Expenses</td><td></td><td>$10 mln</td><td></td></tr></tbody></table></div>Analyst Coverage<ul><li>The current average analyst rating on the shares is &#34;buy&#34; and the breakdown of recommendations is 2 &#34;strong buy&#34; or &#34;buy&#34;, no &#34;hold&#34; and no &#34;sell&#34; or &#34;strong sell&#34;</li><li>The average consensus recommendation for the biotechnology &amp; medical research peer group is &#34;buy&#34;</li><li>Wall Street's median 12-month price target for Collplant Biotechnologies Ltd is $11.50, about 80.5% above its November 25 closing price of $2.24</li></ul>Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</div></div>

CLGN

CollPlant Biotechnologies reported a significant increase in Q3 2025 revenue driven by rhCollagen sales and a $2 million milestone payment from AbbVie. The company announced a 25% workforce reduction to extend its cash runway and plans to expand its North American distribution through a new U.S. logistics partnership. Analysts rate the stock as a "buy," with a median 12-month price target of $11.50, significantly above its current price.

CollPlant Biotechnologies' Q3 revenue rises on rhCollagen sales, cuts workforce